130 related articles for article (PubMed ID: 30454965)
1. TET2 rs2454206, TET2 rs12498609 and ASXL1 rs3746609 single nucleotide polymorphisms in patients with myelodysplastic syndromes.
Hu J; Xu J; Tian T; Xie J; Fan L; Zhu G; Xia T; Chen X; Tan Y; Chen X; Ren F; Zhang Y; Wang H; Xu Z
Blood Cells Mol Dis; 2019 Feb; 74():44-50. PubMed ID: 30454965
[TBL] [Abstract][Full Text] [Related]
2. TET2, ASXL1 and EZH2 mutations in Chinese with myelodysplastic syndromes.
Wang J; Ai X; Gale RP; Xu Z; Qin T; Fang L; Zhang H; Pan L; Hu N; Zhang Y; Xiao Z
Leuk Res; 2013 Mar; 37(3):305-11. PubMed ID: 23099237
[TBL] [Abstract][Full Text] [Related]
3. Myelodysplastic syndromes without peripheral monocytosis but with evidence of marrow monocytosis share clinical and molecular characteristics with CMML.
Schuler E; Frank F; Hildebrandt B; Betz B; Strupp C; Rudelius M; Aul C; Schroeder T; Gattermann N; Haas R; Germing U
Leuk Res; 2018 Feb; 65():1-4. PubMed ID: 29216536
[TBL] [Abstract][Full Text] [Related]
4. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.
Bejar R; Lord A; Stevenson K; Bar-Natan M; Pérez-Ladaga A; Zaneveld J; Wang H; Caughey B; Stojanov P; Getz G; Garcia-Manero G; Kantarjian H; Chen R; Stone RM; Neuberg D; Steensma DP; Ebert BL
Blood; 2014 Oct; 124(17):2705-12. PubMed ID: 25224413
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of TET2 mutations in myelodysplastic syndromes: A meta-analysis.
Guo Z; Zhang SK; Zou Z; Fan RH; Lyu XD
Leuk Res; 2017 Jul; 58():102-107. PubMed ID: 28521175
[TBL] [Abstract][Full Text] [Related]
6. Correlation of TET2 SNP rs2454206 with improved survival in children with acute myeloid leukemia featuring intermediate-risk cytogenetics.
Wang X; Chen X; Yang Z; Dou H; Lu L; Bi J; Zou L; Yu J; Bao L
Genes Chromosomes Cancer; 2018 Aug; 57(8):379-386. PubMed ID: 29664232
[TBL] [Abstract][Full Text] [Related]
7. [TET2 and DLK1 gene expression and their clinical significance in bone marrow CD(3)(+) T cells of patients with myelodysplastic syndrome].
Zhang W; Fu R; Wang HQ; Li LJ; Yue LZ; Liu H; Qu W; Liang Y; Wang GJ; Wang XM; Wu YH; Liu H; Song J; Guan J; Xing LM; Shao ZH
Zhonghua Nei Ke Za Zhi; 2012 Jul; 51(7):543-6. PubMed ID: 22943828
[TBL] [Abstract][Full Text] [Related]
8. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value.
Smith AE; Mohamedali AM; Kulasekararaj A; Lim Z; Gäken J; Lea NC; Przychodzen B; Mian SA; Nasser EE; Shooter C; Westwood NB; Strupp C; Gattermann N; Maciejewski JP; Germing U; Mufti GJ
Blood; 2010 Nov; 116(19):3923-32. PubMed ID: 20693430
[TBL] [Abstract][Full Text] [Related]
9. Acquired mutations in TET2 are common in myelodysplastic syndromes.
Langemeijer SM; Kuiper RP; Berends M; Knops R; Aslanyan MG; Massop M; Stevens-Linders E; van Hoogen P; van Kessel AG; Raymakers RA; Kamping EJ; Verhoef GE; Verburgh E; Hagemeijer A; Vandenberghe P; de Witte T; van der Reijden BA; Jansen JH
Nat Genet; 2009 Jul; 41(7):838-42. PubMed ID: 19483684
[TBL] [Abstract][Full Text] [Related]
10. Dynamics of epigenetic regulator gene BCOR mutation and response predictive value for hypomethylating agents in patients with myelodysplastic syndrome.
Li X; Xu F; Zhang Z; Guo J; He Q; Song LX; Wu D; Zhou LY; Su JY; Xiao C; Chang CK; Wu LY
Clin Epigenetics; 2021 Aug; 13(1):169. PubMed ID: 34461985
[TBL] [Abstract][Full Text] [Related]
11. Ten-eleven-translocation 2 (TET2) is downregulated in myelodysplastic syndromes.
Scopim-Ribeiro R; Machado-Neto JA; Campos Pde M; Silva CA; Favaro P; Lorand-Metze I; Costa FF; Saad ST; Traina F
Eur J Haematol; 2015 May; 94(5):413-8. PubMed ID: 25200248
[TBL] [Abstract][Full Text] [Related]
12. Analysis of core mutation and TET2/ASXL1 mutations DNA methylation profile in myelodysplastic syndrome.
Feng Y; Liang H; Han M; Luo X; Zhu Y; Liu B
Hematology; 2023 Dec; 28(1):2220222. PubMed ID: 37288803
[TBL] [Abstract][Full Text] [Related]
13. TET2, ASXL1, IDH1, and IDH2 Single Nucleotide Polymorphisms in Turkish Patients with Chronic Myeloproliferative Neoplasms.
Soyer N; Tezcanlı Kaymaz B; Cömert Özkan M; Aktan Ç; Küçükaslan AŞ; Şahin F; Kosova B; Saydam G
Turk J Haematol; 2017 Jun; 34(2):174-178. PubMed ID: 28218607
[TBL] [Abstract][Full Text] [Related]
14. Down-regulation of TET2 in CD3⁺ and CD34⁺ cells of myelodysplastic syndromes and enhances CD34⁺ cells proliferation.
Zhang W; Shao Z; Fu R; Wang H; Li L; Liu H
Int J Clin Exp Pathol; 2015; 8(9):10840-6. PubMed ID: 26617797
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of Arginase 1 is linked to DNMT3A and TET2 mutations in lower-grade myelodysplastic syndromes and chronic myelomonocytic leukemia.
Cull AH; Mahendru D; Snetsinger B; Good D; Tyryshkin K; Chesney A; Ghorab Z; Reis M; Buckstein R; Wells RA; Rauh MJ
Leuk Res; 2018 Feb; 65():5-13. PubMed ID: 29227812
[TBL] [Abstract][Full Text] [Related]
16. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.
Itzykson R; Kosmider O; Cluzeau T; Mansat-De Mas V; Dreyfus F; Beyne-Rauzy O; Quesnel B; Vey N; Gelsi-Boyer V; Raynaud S; Preudhomme C; Adès L; Fenaux P; Fontenay M;
Leukemia; 2011 Jul; 25(7):1147-52. PubMed ID: 21494260
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of ASXL1 gene variant in patients with myelodysplastic syndrome].
Chen M; Liu J; Chao H; Qin W; Jiang N; Lu X; Cen L; Jiang Y; Cai X; Zhang R; Wang Q
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2020 Feb; 37(2):110-115. PubMed ID: 32034733
[TBL] [Abstract][Full Text] [Related]
18. Decreased 5-hydroxymethylcytosine levels are associated with TET2 mutation and unfavorable overall survival in myelodysplastic syndromes.
Liu X; Zhang G; Yi Y; Xiao L; Pei M; Liu S; Luo Y; Zhong H; Xu Y; Zheng W; Shen J
Leuk Lymphoma; 2013 Nov; 54(11):2466-73. PubMed ID: 23432690
[TBL] [Abstract][Full Text] [Related]
19. Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations.
Szpurka H; Jankowska AM; Makishima H; Bodo J; Bejanyan N; Hsi ED; Sekeres MA; Maciejewski JP
Leuk Res; 2010 Aug; 34(8):969-73. PubMed ID: 20334914
[TBL] [Abstract][Full Text] [Related]
20. Clinical, biological, and prognostic implications of SF3B1 co-occurrence mutations in very low/low- and intermediate-risk MDS patients.
Janusz K; Izquierdo MM; Cadenas FL; Ramos F; Sánchez JMH; Lumbreras E; Robledo C; Del Real JS; Caballero JC; Collado R; Bernal T; Pedro C; Insunza A; de Paz R; Xicoy B; Salido E; García JS; Mínguez SS; García CM; Muñoz AMS; Barba MS; Rivas JMH; Abáigar M; Campelo MD
Ann Hematol; 2021 Aug; 100(8):1995-2004. PubMed ID: 33409621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
